Hi, have PF, and have been offered a free trip for a week to Las Vegas staying at the Venetian. Would like to travel while I can but is Vegas a smart place to go because of the very relaxed indoor smoking laws? Any advice would be appreciated.
Hi I should clarify, I haven't been officially diagnosed. However, the pattern of my spirometry resembles the pattern of PF according to my cardiologist. My respirologist thinks it may be COPD. Either way, still unsure if it is safe to go to Las Vegas.
JMJ
Hello Marcus,
The best thing to do is check on the Internet of the places that you want to go and see what the smoking policies are. Most places nowadays do not allow smoking !
My best to you and your family
I keep all in my daily prayers
Sincerley Barbara
Thank you Barbara, your advice (and prayers!) are very helpful.
I traveled to Hawaai and LV but I used a concentrator once We got above 8 thousand feet. As for Las Vegas, check the casino, most have non- smoking areas.
Ive had IPF since 2012, I did have the Velcro sound but most off the time I cAnt hear any.
Im on OFEV 200mg and wonder if my diag. Is correct. I feel good most of the time. Ive been zweak since 1990 when I had NH CAN,CER. I now also have a concentrator for the home, no velcro sound , but still not much enegry.
Send toRev Pneumol Clin.1985;41(2):91-100.[Respiratory function and alveolar biological changes under the effect of CDP-choline in pulmonary interstitial pathology: pulmonary fibrosis and sarcoidosis].[Article in French]
Pacheco Y, Douss T, Pujol B, Revol A, Vergnon JM, Biot N, Brune J, Perrin-Fayolle M.Abstract
Various anomalies of pulmonary surfactant have been described in relation to acute respiratory distress syndromes, hypersensitivity lung disease and pulmonary sarcoidosis. Phosphatidylcholine (PC) is the essential phospholipid component of pulmonary surfactant. Cytidine diphosphocholine (CDP-choline) is an essential intermediary in the biosynthesis of PC. The authors studied two groups of patients: one group consisted of diffuse interstitial pulmonary fibrosis and the other consisted of pulmonary sarcoidosis with parenchymal involvement. They observed quantitative and qualitative abnormalities of the phospholipid fractions of surfactant and more particularly of PC. The finding of a marked decrease in this phospholipid, especially in the cases of pulmonary fibrosis, justified the study of the therapeutic effects of CDP-choline. After one month of treatment with this substance, at a dose of 1 g I.M. per day, the PC fraction had returned to normal and, at the same time, there was an improvement in the PaO2 at rest and after exercise. Long term administration of CDP-choline appears to be valuable in the maintenance of the phospholipid equilibrium of pulmonary surfactant and in the improvement of the quality of alveolar gas exchange.